Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Free Cash Flow (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Free Cash Flow data on record, last reported at -$18.1 million in Q4 2023.

  • For Q4 2023, Free Cash Flow rose 29.9% year-over-year to -$18.1 million; the TTM value through Dec 2023 reached -$134.5 million, down 5.23%, while the annual FY2025 figure was -$175.8 million, 20.99% down from the prior year.
  • Free Cash Flow reached -$18.1 million in Q4 2023 per CGEM's latest filing, up from -$34.1 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$1.5 million in Q1 2021 and bottomed at -$54.6 million in Q3 2022.
  • Average Free Cash Flow over 4 years is -$21.0 million, with a median of -$17.2 million recorded in 2021.
  • Peak YoY movement for Free Cash Flow: skyrocketed 69.81% in 2021, then plummeted 1346.07% in 2022.
  • A 4-year view of Free Cash Flow shows it stood at -$9.4 million in 2020, then tumbled by 60.79% to -$15.2 million in 2021, then tumbled by 70.49% to -$25.9 million in 2022, then rose by 29.9% to -$18.1 million in 2023.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$18.1 million in Q4 2023, -$34.1 million in Q3 2023, and -$31.1 million in Q2 2023.